OSOranee Sanmaneechai

Oranee Sanmaneechai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Oranee Sanmaneechai has a total of 331 co-authors. Here are the top co-authors by number of shared publications:

  • Surachai Likasitwattanakul

    Division of Neurology, Department of Pediatrics, Faculty of Medicine Siriraj Hospital Mahidol University Bangkok Thailand

    9 shared publications
  • Pimchanok Kulsirichawaroj

    Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand; Center of Research Excellence for Neuromuscular Diseases, Faculty of Medicine, Siriraj Hospital, Mahidol University, Thailand

    8 shared publications
  • Chanin Limwongse

    Siriraj Genomics, Office of the Dean, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

    4 shared publications
  • Pimchanok Kulsirichawaroj

    Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

    4 shared publications
  • Theeraphong Pho-Iam

    Siriraj Genomics, Office of the Dean, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand

    4 shared publications
  • Vorasuk Shotelersuk

    Center of Excellence for Medical Genomics, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

    4 shared publications

Latest Publications

  • Open Access

    Axonal-demyelinating differences in functional change in pediatric Charcot–Marie–Tooth and related neuropathies

    by Chonlada Inmongkol, Nutchavadee Vorasan, Sivaporn Limpaninlachat, Niramon Sereephaowong, Pimchanok Kulsirichawaroj, Oranee Sanmaneechai, Joshua Burns

    Charcot–Marie–Tooth disease and related neuropathies (CMTR) are heterogeneous inherited neuropathies with variable progression, yet data on ped

  • Open Access

    Expanding the Genetic Landscape of Congenital Insensitivity to Pain

    by Theeraphong Pho-Iam, Pimchanok Kulsirichawaroj, Surachai Likasitwattanakul, Numpueng Ridchuayrod, Oranee Sanmaneechai, Chanin Limwongse, Stephan Zuchner

    Congenital insensitivity to pain (CIP) is a rare sensory neuropathy marked by absent nociception that predisposes patients to injuries and complications. Variants in genes, particularly PRDM12, underlie the condition. We investigated the molecular basis of CIP in 2 unrelated families. Trio whole-exome sequencing was performed for 3 CIP patients from 2 unrelated families and their parents; 1 family with negative results subsequently underwent whole genome sequencing. Sanger sequencing and fluorescent PCR confirmed and sized a GCC repeat expansion. PRDM12 variants explained CIP in both families, each manifesting infantile-onset neuropathic keratopathy and self-mutilation. In Family 1, 2 siblings born to consanguineous parents were homozygous for a 19-GCC repeat expansion in the last exon, resulting in a polyalanine tract of 20 alanines—the largest PRDM12 polyalanine expansion reported to date. In Family 2, the proband carried 2 compound-heterozygous variants c.570+2T > G and c.796A > C (p.Thr266Pro) classified as pathogenic and likely pathogenic, respectively, and both previously undescribed. These data broaden the genetic spectrum of CIP and reinforce PRDM12 as a key gene in pain perception. They also emphasize that diagnostic analysis should target both single-nucleotide variants and polyalanine expansions, which are often underrepresented in whole-exome or whole-genome sequencing data.


  • Open Access

    Validation and Reliability of the Thai Pediatric Charcot–Marie–Tooth Quality of Life Outcome Measure

    by Pimchanok Kulsirichawaroj, Arisa Phochaisarn, Sivaporn Limpaninlachat, Nutchavadee Vorasan, Surachai Likasitwattanakul, Sindhu Ramchandren, Michael E. Shy, Oranee Sanmaneechai

    Background and Aims: Charcot–Marie–Tooth disease (CMT) is a hereditary neuropathy that causes progressive muscle weakness, sensory deficits, and impaired mobility, significantly affecting quality of life (QoL). The Pediatric Charcot–Marie–Tooth Quality of Life (pCMT‐QoL) instrument was developed specifically for children with CMT. However, a validated Thai version is not yet available. Methods: We conducted a cross‐sectional study at the Pediatric Neuromuscular Clinic from July 2023 to December 2024. Using a forward–backward translation method, we adapted the pCMT‐QoL into Thai. Twenty‐three children with CMT and their caregivers completed the Thai questionnaire. We evaluated internal consistency using Cronbach's alpha and test–retest reliability using intraclass correlation coefficients (ICCs). Convergent validity was examined via Pearson correlation between child self‐reports and parent‐proxy reports across functional, mental, and physical domains. Results: The Thai pCMT‐QoL demonstrated high test–retest reliability (ICC > 0.85) and satisfactory internal consistency (Cronbach's alpha > 0.7) across most domains. Convergent validity was strong for the total and mental domains but weaker for the physical domain, reflecting differences in perception between children and parents. Parents generally reported higher QoL scores than children did, a finding consistent with studies in other neuromuscular diseases. Most participants completed the questionnaire within 15 min, suggesting good feasibility. Interpretation: The Thai pCMT‐QoL is a reliable, culturally adapted tool for assessing QoL in children with CMT. It is suitable for both remote and in‐clinic administration. Future studies with larger cohorts are needed to confirm its responsiveness to clinical changes and to broaden its application in diverse settings.

  • Open Access

    Next-generation sequencing for pediatric-onset neuromuscular disorders unresolved by conventional diagnostic methods

    by Pimchanok Kulsirichawaroj, Mongkol Chanvanichtrakool, Pish Wattanadilokchatkun, Theeraphong Pho-Iam, Chanin Limwongse, Surachai Likasitwattanakul, Kanokwan Boonyapisit, Oranee Sanmaneechai, Ichizo Nishino, Vorasuk Shotelersuk, et al.

    Background: Neuromuscular disorders (NMDs), rare diseases affecting the peripheral nervous system, often cause progressive weakness and systemic complications. Despite advances in genetic diagnostics, data from Southeast Asia remain limited. Ancestral variation may influence mutation spectra, revealing novel alleles and phenotypic diversity. Methods: We evaluated the diagnostic yield and clinical impact of targeted gene panel testing and exome sequencing in pediatric-onset NMDs at Siriraj Hospital, Thailand (2020‒2024). Patients with suspected genetic NMDs and negative single-gene tests underwent gene panel testing or exome sequencing. Genetic findings were classified as positive, probable, possible, or negative. Results: Among 135 patients, the overall diagnostic yield was 69.6% (94/135). Subgroup yields were 70.7% for inherited myopathies (53/75), 63.3% for inherited neuropathies (31/49), 90.0% for congenital myasthenic syndromes (9/10), and 100% for motor neuron diseases (1/1). Excluding patients with Duchenne muscular dystrophy, the diagnostic yield of inherited myopathies was 63.2% (36/57). Genetic diagnoses influenced clinical care in 87.2% of cases, prompting revised diagnoses, personalized treatments, enhanced surveillance, informed family planning, and accurate prognostication. Conclusions: NGS substantially enhances diagnostic accuracy and clinical management for pediatric NMDs. These findings support incorporating NGS into diagnostic workflows for suspected genetic NMDs, thereby optimizing patient care and advancing genetic insights. Impact: Gene panel testing and exome sequencing demonstrate an approximately 70% diagnostic yield for pediatric neuromuscular disorders, exceeding yields reported in many other hereditary diseases. Genetic findings underscore potential differences in mutation spectra among Southeast Asian populations, which remain under-investigated relative to Western cohorts. Clinical implementation of next-generation sequencing confers substantial benefits, including more accurate diagnoses, personalized management, and informed family planning, ultimately improving care for pediatric neuromuscular disorders.


  • Open Access

    Fatal outcomes following onasemnogene abeparvovec in advanced-stage spinal muscular atrophy

    by Peerada Pongsakornkullachart, Pimchanok Kulsirichawaroj, Ratcharin Kongkasuwan, Prakarn Tovichien, Settapong Jitwongwai, Supaluck Kanjanauthai, Nutnicha Preeprem, Sivaporn Limpaninlachat, Nisasri Sermpon, Oranee Sanmaneechai

    Supported by encouraging trial outcomes, onasemnogene abeparvovec (OA) was authorized for spinal muscular atrophy (SMA). Nevertheless, efficacy of OA in advanced SMA patients remains underexplored. This investigation assessed clinical effectiveness and adverse effects of OA in a cohort including advanced SMA, and compared to historical survival data for SMA type 1 patients in Thailand. We conducted observational cohort study at Siriraj Hospital, Thailand, from May 2019 to April 2022. The study enrolled eight SMA patients receiving OA therapy. The cohort comprised five SMA type 1 patients treated at 16.7 months (6.5–24.9 months) and three SMA type 2 patients treated at 20.3 months (19–31.5 months). Before receiving OA, all Type 1 patients required 24-hour invasive ventilation and feeding support. Post-treatment, Three of five showed gradual improvement in motor scores, but none achieved new motor milestones. Survival rate was not improved, with all experiencing fatalities. Conversely, Type 2 patients exhibited motor score improvement without serious adverse events. OA did not significantly improve clinical outcomes or survival rates in advanced Type 1 SMA. These findings highlight need for additional caution when administering OA to severe SMA Type 1 and more specific guidelines in selecting subgroups for treatment.


  • Open Access

    Gene-based therapy for the treatment of spinal muscular atrophy types 1 and 2 : a systematic review and meta-analysis

    by Bunchai Chongmelaxme, Varalee Yodsurang, Ponlawat Vichayachaipat, Thanate Srimatimanon, Oranee Sanmaneechai

    Despite numerous studies identifying the advantages of therapies for spinal muscular atrophy (SMA), healthcare professionals encounter obstacles in determining the most effective treatment. This study aimed to investigate the effects of gene-based therapy for SMA. A systematic search was conducted from inception to May 2024 across databases, and all studies assessing the effects of gene-based therapy on patients with SMA types 1 and 2 were included. The outcomes measured were survival, the need for ventilatory support, improvements in motor function, and the occurrence of adverse drug reactions. Meta-analyses were performed using a random-effects model. A total of 57 studies (n = 3418) were included, and the meta-analyses revealed that onasemnogene abeparvovec showed the highest survival rate (95% [95% CI: 88, 100]), followed by risdiplam (86% [95% CI: 76, 94]) and nusinersen (60% [95% CI: 50, 70]). The number of patients needing ventilatory support was reduced after treatment with onasemnogene abeparvovec (risk ratio = 0·10 [95% CI: 0·02, 0·53]). Onasemnogene abeparvovec and risdiplam had similar proportions of patients with improvements in the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders score of ≥4 points (92% [95% CI: 62, 100] vs 90% [95% CI: 77, 97]). In contrast, nusinersen had the smallest improvement (74% [95% CI: 66, 81]). The most frequently observed adverse drug reactions were headaches, vomiting, and gastrointestinal disorders. Gene-based therapy benefits patient survival and improves motor function. Onasemnogene abeparvovec and risdiplam appear highly effective, whereas nusinersen exhibits moderate effectiveness.


  • Open Access

    Onasemnogene Abeparvovec Gene Therapy and Risdiplam for the Treatment of Spinal Muscular Atrophy in Thailand: A Cost-Utility Analysis

    by Sarayuth Khuntha, Juthamas Prawjaeng, Kunnatee Ponragdee, Oranee Sanmaneechai, Varalak Srinonprasert, Pattara Leelahavarong

    Objectives Caring for individuals with spinal muscular atrophy (SMA), a rare genetic disorder, poses tremendous challenges for the economy and healthcare system. This study evaluated the cost-utility of onasemnogene abeparvovec-xioi gene therapy and risdiplam for SMA in Thailand. Methods A Markov model was used to analyze the lifetime costs and outcomes of these treatments compared with standard of care for symptomatic SMA types 1 and 2–3. SMA type 1 patients were treated with one of either onasemnogene or risdiplam, while SMA types 2–3 patients received risdiplam. Data on disease progression and medical costs were sourced from hospital databases, while treatment efficacy was based on clinical trials. Interviews with patients and caregivers provided data on non-medical costs and utilities. Base case cost-effectiveness and sensitivity analyses were conducted, with the incremental cost-effectiveness ratio (ICER) calculated in US dollars (USD) per quality-adjusted life year (QALY) gained, against a willingness-to-pay threshold of 4444 USD/QALY gained. Results For SMA type 1, the ICERs for onasemnogene and risdiplam were 163,102 and 158,357 USD/QALY gained, respectively. For SMA types 2–3, the ICER for risdiplam was 496,704 USD/QALY gained. Conclusions While onasemnogene and risdiplam exceeded the value-for-money threshold of the Thai healthcare system, they yielded the highest QALY gains among all approved medications. Policy-makers should incorporate various pieces of evidence alongside the cost-effectiveness results for rare diseases with costly drugs. Additionally, cost-effectiveness findings are useful for price negotiations and alternative financial funding, which allows policy-makers to seek solutions to ensure patient access, aligning with universal health coverage principles in Thailand.


  • Open Access

    Spinal muscular atrophy in an upper-middle-income nation before the advent of reimbursed disease-modifying therapies

    by Kullasate Sakpichaisakul, Kamornwan Katanyuwong, Utcharee Intusoma, Tanitnun Paprad, Piradee Suwanpakdee, Chaiyos Khongkhatithum, Oranee Sanmaneechai

    Objective To elucidate the clinical characteristics and standard of care (SoC) of spinal muscular atrophy (SMA) patients in Thailand, focusing on primary endpoints: age at death and a composite of death or tracheostomy need. Design Retrospective observational study. Setting Seven tertiary centres across Thailand. Patients Records of 110 patients with genetically confirmed SMA, spanning 2012–2021. Interventions Historical data review; no active interventions. Main outcome measures Age at death and a composite measure of death or tracheostomy necessity. Results The cohort included 1 SMA0, 50 SMA1, 40 SMA2 and 19 SMA3 cases. Median ages at the onset and diagnosis of SMA1 were 3 and 6.2 months. Of SMA1 patients, 63% required ventilators, and eight received dimethyltryptamines (DMTs) at a median of 15 months (range 6.4–24.5 months). The median time from onset to DMT was 11 months (range 4.2–20.5 months). Among SMA1 patients, 73% died by the study’s end. SMA2 and SMA3 patients' median onset ages were 11 and 24 months, respectively, with diagnosis at 24.8 and 68.7 months. Half of all types received physical therapy. Conclusions Significant delays in diagnosis and SoC access, including DMTs, were observed, underscoring urgent needs for improved diagnostic and care strategies to enhance SMA patient outcomes in Thailand.


  • Open Access

    Survival analysis and life expectancy of pediatric patients with spinal muscular atrophy in Thailand

    by Piyanart Sittiyuno, Pimchanok Kulsirichawaroj, Pattara Leelahavarong, Oranee Sanmaneechai